Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial

<div>Kaplan-Meier survival analysis with the first treatments interruption as outcome (HIV and tuberculosis) according to trial arm. Dark shade area shows EFV800’s survival curve confidence band and light shade shows EFV600’s survival curve confidence band (CI=95%). Hazard ratios were calculated as hazard of EFV800 over hazard of EFV600.</div>

BioMed Research International

fig6

Figure 6

Figure 6: Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial 

Figure 6 | Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial 